Evidence map›Paper›PMID 37568822›Full record

ReviewCancers2023

Emerging Role of Epigenetic Modifiers in Breast Cancer Pathogenesis and Therapeutic Response.

Richard Sean Lee, Kirti Sad, Dorelle V Fawwal, Jennifer Marie Spangle

Abstract readReview
In one paragraph

Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Decoding the Epigenome of Breast Cancer.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. ACSL4-mediated H3K9 and H3K27 hyperacetylation upregulates SNAIL to drive TNBC metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  12. Review
  13. Epigenetic Cancer Therapy.Indian journal of surgical oncology · 2024
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Richard Sean LeeDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0003-1775-715X
Kirti SadDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-5012-076X
Dorelle V FawwalDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Jennifer Marie SpangleDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-0181-3244

Funding

Training Program in Biochemistry, Cell and Molecular BiologyT32GM135060 · NIGMS · EMORY UNIVERSITY · PI Lawrence H. Boise, ANITA H. CORBETT · 2020 to 2026
$2.8M
The PI3K/AKT Pathway Regulates Histone H3 ModificationR00CA204601 · NCI · EMORY UNIVERSITY · PI SPANGLE, JENNIFER MARIE · 2019 to 2021
$747k
The role of novel oncogenic histone H3 lysine variants in defining a therapeutically actionable epigenetic signatureR21CA256456 · NCI · EMORY UNIVERSITY · PI CORBETT, ANITA H., SPANGLE, JENNIFER MARIE · 2021 to 2022
$389k
NCI NIH HHS R00 CA204601NCI NIH HHS R00CA204601NCI NIH HHS R21 CA256456NIGMS NIH HHS T32 GM135060
6 · The paper itself

Abstract

Breast cancer pathogenesis, treatment, and patient outcomes are shaped by tumor-intrinsic genomic alterations that divide breast tumors into molecular subtypes. These molecular subtypes often dictate viable therapeutic interventions and, ultimately, patient outcomes. However, heterogeneity in therapeutic response may be a result of underlying epigenetic features that may further stratify breast cancer patient outcomes. In this review, we examine non-genetic mechanisms that drive functional changes to chromatin in breast cancer to contribute to cell and tumor fitness and highlight how epigenetic activity may inform the therapeutic response. We conclude by providing perspectives on the future of therapeutic targeting of epigenetic enzymes, an approach that holds untapped potential to improve breast cancer patient outcomes.

Indexed as

breast cancerchromatin modificationepigeneticsHATHDAChistone acetylationhistone methylation

Identifiers

PMID37568822
PMCPMC10417282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.